Mendus AB (publ) (STO:IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.06
+0.09 (1.71%)
May 22, 2025, 11:38 AM CET
-44.52%
Market Cap 250.54M
Revenue (ttm) -1.44M
Net Income (ttm) -123.27M
Shares Out 50.36M
EPS (ttm) -2.45
PE Ratio n/a
Forward PE 23.82
Dividend n/a
Ex-Dividend Date n/a
Volume 5,158
Average Volume 20,077
Open 4.98
Previous Close 4.98
Day's Range 4.85 - 5.13
52-Week Range 4.46 - 11.20
Beta 0.68
RSI 42.63
Earnings Date Aug 21, 2025

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 28
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.